177
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Disease Trajectories and Impact of One Moderate Exacerbation in Gold B COPD Patients

ORCID Icon, , ORCID Icon, , , ORCID Icon & ORCID Icon show all
Pages 569-578 | Published online: 16 Mar 2022

References

  • GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease; 2021.
  • Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet. 2009;374(9691):744–755. doi:10.1016/S0140-6736(09)61342-8
  • Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422. doi:10.1164/ajrccm.157.5.9709032
  • Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.040527
  • Løkke A, Lange P, Lykkegaard J, et al. Economic burden of COPD by disease severity - A nationwide cohort study in Denmark. Int J Chron Obstruct Pulmon Dis. 2021;16:603–613. doi:10.2147/COPD.S295388
  • Mason SE, Moreta-Martinez R, Labaki WW, et al. Respiratory exacerbations are associated with muscle loss in current and former smokers. Thorax. 2021;76(6):554–560. doi:10.1136/thoraxjnl-2020-215999
  • Rothnie KJ, Mullerova H, Smeeth L, Quint JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice-based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(4):464–471. doi:10.1164/rccm.201710-2029OC
  • Ho TW, Tsai YJ, Ruan SY, Huang CT, Lai F, Yu CJ. In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study. PLoS One. 2014;9(12):e114866. doi:10.1371/journal.pone.0114866
  • Agustí A, Celli B. Natural history of COPD: gaps and opportunities. ERJ Open Res. 2017;3(4):00117–2017. doi:10.1183/23120541.00117-2017
  • Ulrik CS, Vijverberg S, Hanania NA, Diamant Z. Precision medicine and treatable traits in chronic airway diseases - where do we stand? Curr Opin Pulm Med. 2020;26(1):33–39. doi:10.1097/MCP.0000000000000639
  • Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–419. doi:10.1183/13993003.01359-2015
  • Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42(3):636–646. doi:10.1183/09031936.00195212
  • Lawrence PJ, Kolsum U, Gupta V, et al. Characteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patients. BMC Pulm Med. 2017;17(1):42. doi:10.1186/s12890-017-0384-8
  • Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490. doi:10.2147/CLEP.S91125
  • Lange P, Tottenborg SS, Sorknaes AD, et al. Danish register of chronic obstructive pulmonary disease. Clin Epidemiol. 2016;8:673–678. doi:10.2147/CLEP.S99489
  • Pottegard A, Schmidt SAJ, Wallach-Kildemoes H, Sorensen HT, Hallas J, Schmidt M. Data resource profile: the Danish National Prescription Registry. Int J Epidemiol. 2017;46(3):798–798f. doi:10.1093/ije/dyw213
  • Schmidt M, Pedersen L, Sorensen HT. The Danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549. doi:10.1007/s10654-014-9930-3
  • Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011;39(7 Suppl):26–29. doi:10.1177/1403494811399958
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-8
  • Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509. doi:10.1080/01621459.1999.10474144
  • Punekar YS, Mullerova H, Small M, et al. Prevalence and burden of dyspnoea among patients with chronic obstructive pulmonary disease in five European countries. Pulm Ther. 2016;2(1):59–72. doi:10.1007/s41030-016-0011-5
  • Casanova C, Marin JM, Martinez-Gonzalez C, et al. Differential effect of modified medical research council dyspnea, COPD assessment test, and clinical COPD questionnaire for symptoms evaluation within the new GOLD staging and mortality in COPD. Chest. 2015;148(1):159–168. doi:10.1378/chest.14-2449
  • Larsson K, Janson C, Lisspers K, et al. The impact of exacerbation frequency on clinical and economic outcomes in Swedish COPD patients: the ARCTIC study. Int J Chron Obstruct Pulmon Dis. 2021;16:701–713. doi:10.2147/COPD.S297943
  • Sundh J, Åberg J, Hasselgren M, et al. Factors influencing pharmacological treatment in COPD: a comparison of 2005 and 2014. Eur Clin Respir J. 2017;4(1):1409060. doi:10.1080/20018525.2017.1409060
  • Graf J, Jörres RA, Lucke T, Nowak D, Vogelmeier CF, Ficker JH. Medical treatment of COPD. Dtsch Arztebl Int. 2018;155(37):599–605. doi:10.3238/arztebl.2018.0599
  • Ding B, Small M, Holmgren U. A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications. Int J Chron Obstruct Pulmon Dis. 2017;12:1527–1537. doi:10.2147/COPD.S133793
  • Gedebjerg A, Szépligeti SK, Wackerhausen LH, et al. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new global initiative for chronic obstructive lung disease 2017 classification: a cohort study. Lancet Respir Med. 2018;6(3):204–212. doi:10.1016/S2213-2600(18)30002-X